Pharmaceutical companies that fail to get involved in disease prevention will ‘get left behind,’ delegates at an international conference have been told.
Speaking at the 14th annual eyeforpharma conference in Barcelona, Spain, this week, Sanofi Pasteur’s chief operating officer David Loew, warned that, as the industry moves away from sales force driven models to more collaborative models, it was vital that pharma took its seat at the ‘disease prevention’ table.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze